Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
Multiple extracranial metastases of recurrent glioblastoma are rare and often indicate a very poor prognosis. The main conventional treatments are chemotherapy, radiotherapy, chemoradiotherapy or antiangiogenic therapy. Median overall survival is 2.3 to 6 months after the detection of extracranial m...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.948933/full |
| _version_ | 1798040063179751424 |
|---|---|
| author | Gang Yang Yu Fang Ming Zhou Wei Li Dapeng Dong Jing Chen Yong Da Kunpeng Wang Xinru Li Xiaoyan Zhang Tonghui Ma Ge Shen |
| author_facet | Gang Yang Yu Fang Ming Zhou Wei Li Dapeng Dong Jing Chen Yong Da Kunpeng Wang Xinru Li Xiaoyan Zhang Tonghui Ma Ge Shen |
| author_sort | Gang Yang |
| collection | DOAJ |
| description | Multiple extracranial metastases of recurrent glioblastoma are rare and often indicate a very poor prognosis. The main conventional treatments are chemotherapy, radiotherapy, chemoradiotherapy or antiangiogenic therapy. Median overall survival is 2.3 to 6 months after the detection of extracranial metastases, and to date, there is no effective treatment for these patients. Herein, we report a recurrent glioblastoma patient with lung metastasis treated with a combination therapy containing bevacizumab and pembrolizumab due to overexpression of PD-L1 and the absence of driver mutations. The progression-free survival was 11 months from lung metastases to bone metastases. This combination treatment was further used as maintenance therapy for another 11 months after bone metastasis and secondary dorsal metastasis because there was no suitable treatment alternative. The overall survival was 27 months after lung metastases, which is much longer than previously reported cases. To our knowledge, this was the first effective use of bevacizumab plus pembrolizumab in a glioblastoma patient with extracranial metastases. Furthermore, this was the first time that bevacizumab plus pembrolizumab was used as a maintenance treatment in glioblastoma, with 11 months of response. Importantly, we showed that such combination therapy may be a novel and effective therapy for glioblastoma patients with extracranial metastases. |
| first_indexed | 2024-04-11T22:02:20Z |
| format | Article |
| id | doaj.art-95bc37649e4b4707b35dc4d68cd2aa93 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T22:02:20Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-95bc37649e4b4707b35dc4d68cd2aa932022-12-22T04:00:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.948933948933Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastasesGang Yang0Yu Fang1Ming Zhou2Wei Li3Dapeng Dong4Jing Chen5Yong Da6Kunpeng Wang7Xinru Li8Xiaoyan Zhang9Tonghui Ma10Ge Shen11Oncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaGenetron Health (Beijing) Technology, Co. Ltd., Beijing, ChinaOncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaGenetron Health (Beijing) Technology, Co. Ltd., Beijing, ChinaOncology Department, Beijing Hui’an TCM-Integrated Hospital, Beijing, ChinaGenetron Health (Beijing) Technology, Co. Ltd., Beijing, ChinaOncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaOncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaOncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaGenetron Health (Beijing) Technology, Co. Ltd., Beijing, ChinaGenetron Health (Beijing) Technology, Co. Ltd., Beijing, ChinaOncology Department, Beijing Fengtai You’anmen Hospital, Beijing, ChinaMultiple extracranial metastases of recurrent glioblastoma are rare and often indicate a very poor prognosis. The main conventional treatments are chemotherapy, radiotherapy, chemoradiotherapy or antiangiogenic therapy. Median overall survival is 2.3 to 6 months after the detection of extracranial metastases, and to date, there is no effective treatment for these patients. Herein, we report a recurrent glioblastoma patient with lung metastasis treated with a combination therapy containing bevacizumab and pembrolizumab due to overexpression of PD-L1 and the absence of driver mutations. The progression-free survival was 11 months from lung metastases to bone metastases. This combination treatment was further used as maintenance therapy for another 11 months after bone metastasis and secondary dorsal metastasis because there was no suitable treatment alternative. The overall survival was 27 months after lung metastases, which is much longer than previously reported cases. To our knowledge, this was the first effective use of bevacizumab plus pembrolizumab in a glioblastoma patient with extracranial metastases. Furthermore, this was the first time that bevacizumab plus pembrolizumab was used as a maintenance treatment in glioblastoma, with 11 months of response. Importantly, we showed that such combination therapy may be a novel and effective therapy for glioblastoma patients with extracranial metastases.https://www.frontiersin.org/articles/10.3389/fonc.2022.948933/fullextracranial metastases glioblastomabevacizumabpembrolizumabcombined treatmentcase report |
| spellingShingle | Gang Yang Yu Fang Ming Zhou Wei Li Dapeng Dong Jing Chen Yong Da Kunpeng Wang Xinru Li Xiaoyan Zhang Tonghui Ma Ge Shen Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases Frontiers in Oncology extracranial metastases glioblastoma bevacizumab pembrolizumab combined treatment case report |
| title | Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| title_full | Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| title_fullStr | Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| title_full_unstemmed | Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| title_short | Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| title_sort | case report the effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases |
| topic | extracranial metastases glioblastoma bevacizumab pembrolizumab combined treatment case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.948933/full |
| work_keys_str_mv | AT gangyang casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT yufang casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT mingzhou casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT weili casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT dapengdong casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT jingchen casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT yongda casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT kunpengwang casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT xinruli casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT xiaoyanzhang casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT tonghuima casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases AT geshen casereporttheeffectiveresponsetopembrolizumabincombinationwithbevacizumabinthetreatmentofarecurrentglioblastomawithmultipleextracranialmetastases |